SCHEMBL28942020

SCHEMBL28942020

C[S+]([O-])c1ncc2cc(OC(=O)c3ccccc3)nc(-c3ccccc3)c2n1

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 7/20 0.37
MAPT P10636 5/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
HPGD P15428 2/20 0.37
KDM4E B2RXH2 1/20 0.37
LMNA P02545 3/20 0.35
METAP2 P50579 1/20 0.35
METAP1 P53582 1/20 0.35
HDAC6 Q9UBN7 1/20 0.35
ALDH1A1 P00352 2/20 0.35
MAPK1 P28482 1/20 0.35
ATM Q13315 1/20 0.35
GRM5 P41594 1/20 0.34
NPC1 O15118 1/20 0.34
MEN1 O00255 2/20 0.34
TDP1 Q9NUW8 1/20 0.34
HSP90AA1 P07900 1/20 0.33
USP2 O75604 1/20 0.32
HSD17B10 Q99714 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20203398 0.82 PDCD1 (0.36) KMT2AMAPTSMN1; SMN2HPGDKDM4E
SCHEMBL21403201 0.82 PDCD1 (0.36) KMT2AMAPTSMN1; SMN2HPGDKDM4E
SCHEMBL28755052 0.80 TP53 (0.47) KMT2AMAPTSMN1; SMN2HPGDKDM4E
SCHEMBL23733434 0.69 NPC1 (0.33) KMT2ASMN1; SMN2LMNAALDH1A1NPC1
SCHEMBL20037707 0.69 NPSR1 (0.35) KMT2AMAPTSMN1; SMN2LMNAALDH1A1
SCHEMBL23733435 0.68 MEN1 (0.35) KMT2ALMNAALDH1A1MAPK1NPC1
SCHEMBL20203415 0.68 LMNA (0.33) LMNANPC1
SCHEMBL21403227 0.66 AKT1 (0.34) KMT2AMAPTSMN1; SMN2HPGDKDM4E
SCHEMBL29048993 0.65 KMT2A (0.41) KMT2AMAPTSMN1; SMN2HPGDKDM4E
SCHEMBL25271973 0.64 SMN1; SMN2 (0.40) KMT2AMAPTSMN1; SMN2HPGDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110036012-B Pyrido [3,4-d ] pyrimidine derivatives and pharmaceutically acceptable salts thereof 帝人制药株式会社 2022-05-10 CN disclosed